07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Ceftaroline fosamil: Development discontinued

Dainippon Sumitomo disclosed in its earnings for the fiscal year ended March 31 that it discontinued development of DSP-5990, which was in Phase I testing to treat MRSA infection. The company said the antibiotic did...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Basilea, GlaxoSmithKline sales and marketing update

Basilea granted GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary exclusive, worldwide rights to the Swiss company's only marketed drug, eczema therapy Toctino alitretinoin. Basilea will receive L146 million ($226.3 million) up front and is eligible...
07:00 , Apr 5, 2012 |  BC Innovations  |  Cover Story

MRSA sensitivity training

Researchers at Merck & Co. Inc. have identified targets in methicillin-resistant Staphylococcus aureus that synergize with b-lactam antibiotic targets to restore antibiotic sensitivity.1 The findings suggest it may now be possible to use combinations of...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Doribax: Phase III halted

Johnson & Johnson said in a Dear Healthcare Professional letter that it terminated a double-blind, international Phase III trial after an interim analysis showed a numerically higher mortality and a numerically poorer clinical cure rate...
08:00 , Nov 14, 2011 |  BioCentury  |  Regulation

Inching toward feasibility

Clinical work on compounds to treat community-acquired bacterial pneumonia and hospital-acquired or ventilator-associated bacterial pneumonia has been in limbo since 2008 when FDA began reassessing its requirements for clinical trial designs, which many companies said...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Clinical News

Cayston aztreonam lysine: Additional Phase III data

Additional data from the open-label, U.S. and European Phase III Study 205-0110 trial in 268 patients showed that Cayston met the co-primary endpoint of superiority to inhaled tobramycin in mean change in percent predicted FEV1...
07:00 , Sep 13, 2010 |  BioCentury  |  Regulation

Complicated but uncontroversial

Last week's FDA panel meeting to discuss ceftaroline from Forest Laboratories Inc. was devoid of the controversy that has surrounded reviews of other antibiotics to treat either community-acquired bacterial pneumonia or complicated skin and skin...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Clinical News

Cayston aztreonam lysine: Phase III data

In the open-label, U.S. and European Phase III Study 205-0110 trial in 268 patients, Cayston met the co-primary endpoint of non-inferiority to inhaled tobramycin in mean percent change from baseline in percent predicted FEV1 at...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

AdvanDx, Inverness sales and marketing update

AdvanDx launched the BinaxNOW PBP2a test in the U.S. to identify methicillin-resistant Staphylococcus aureus (MRSA). The test detects the penicillin-binding protein (PBP) 2a in blood samples that have tested positive for S. aureus. AdvanDx has...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

PTZ601: Development discontinued

Novartis disclosed that last quarter it discontinued development of PTZ601 after a high rate of adverse events was observed in a Phase I trial. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: PTZ601   Business: Infectious   Molecular...